Clinical Trial

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Trial Details
NCT Number NCT07449780
Lead Sponsor Akeso
Conditions Gastric / Gastroesophageal Junction Adenocarcinoma
Enrollment 422 participants
Start Date 2026-03-31
Primary Completion 2027-11-17 (estimated)
Study Completion 2028-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-04